Jpmorgan Chase & CO Aclaris Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 498,721 shares of ACRS stock, worth $728,132. This represents 0.0% of its overall portfolio holdings.
Number of Shares
498,721
Previous 88,320
464.68%
Holding current value
$728,132
Previous $219,000
248.4%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ACRS
# of Institutions
112Shares Held
92.9MCall Options Held
35.4KPut Options Held
32K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$20.8 Million17.65% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.63MShares$14.1 Million0.03% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$13 Million3.69% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD5.05MShares$7.37 Million0.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.97MShares$7.26 Million0.0% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $97.3M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...